End-of-day quote
Shanghai S.E.
03:30:00 28/06/2024 am IST
|
5-day change
|
1st Jan Change
|
4.35
CNY
|
+3.82%
|
|
-3.97%
|
-33.38%
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,805
|
4,279
|
2,850
|
-
|
-
|
Enterprise Value (EV)
1 |
5,805
|
4,279
|
2,850
|
2,850
|
2,850
|
P/E ratio
|
-23.3
x
|
-10.2
x
|
-6.74
x
|
-6.96
x
|
-12.1
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
120
x
|
47.1
x
|
17.7
x
|
11.2
x
|
7.34
x
|
EV / Revenue
|
120
x
|
47.1
x
|
17.7
x
|
11.2
x
|
7.34
x
|
EV / EBITDA
|
-26.2
x
|
-10.6
x
|
-7.75
x
|
-9.69
x
|
-
|
EV / FCF
|
-
|
-12.7
x
|
-6.16
x
|
-7.46
x
|
-6.93
x
|
FCF Yield
|
-
|
-7.87%
|
-16.2%
|
-13.4%
|
-14.4%
|
Price to Book
|
4.79
x
|
5.13
x
|
34.8
x
|
-4.22
x
|
19.8
x
|
Nbr of stocks (in thousands)
|
6,55,210
|
6,55,210
|
6,55,210
|
-
|
-
|
Reference price
2 |
8.860
|
6.530
|
4.350
|
4.350
|
4.350
|
Announcement Date
|
24/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
7.66
|
48.21
|
90.78
|
161
|
255.5
|
388.5
|
EBITDA
1 |
-
|
-221.4
|
-405.2
|
-368
|
-294
|
-
|
EBIT
1 |
-
|
-222.9
|
-410.9
|
-418
|
-405.5
|
-235
|
Operating Margin
|
-
|
-462.46%
|
-452.65%
|
-259.63%
|
-158.71%
|
-60.49%
|
Earnings before Tax (EBT)
1 |
-
|
-220.3
|
-415.2
|
-419.5
|
-407
|
-234
|
Net income
1 |
-226.3
|
-220.3
|
-421.1
|
-423.2
|
-410.6
|
-234.1
|
Net margin
|
-2,953.92%
|
-456.99%
|
-463.91%
|
-262.86%
|
-160.7%
|
-60.25%
|
EPS
2 |
-
|
-0.3800
|
-0.6400
|
-0.6450
|
-0.6250
|
-0.3600
|
Free Cash Flow
1 |
-
|
-
|
-336.7
|
-463
|
-382
|
-411
|
FCF margin
|
-
|
-
|
-370.96%
|
-287.58%
|
-149.51%
|
-105.79%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
18/07/22
|
24/02/23
|
22/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-337
|
-463
|
-382
|
-411
|
ROE (net income / shareholders' equity)
|
-
|
-29.5%
|
-41.1%
|
-125%
|
-440%
|
-160%
|
ROA (Net income/ Total Assets)
|
-
|
-20.5%
|
-31.2%
|
-41.2%
|
-41.5%
|
-33.7%
|
Assets
1 |
-
|
1,073
|
1,349
|
1,028
|
990.6
|
694.5
|
Book Value Per Share
2 |
-
|
1.850
|
1.270
|
0.1300
|
-1.030
|
0.2200
|
Cash Flow per Share
2 |
-
|
-0.3700
|
-0.5000
|
-0.6600
|
-0.5600
|
-0.3700
|
Capex
1 |
-
|
10.7
|
7.66
|
20.5
|
13
|
10.5
|
Capex / Sales
|
-
|
22.15%
|
8.44%
|
12.73%
|
5.09%
|
2.7%
|
Announcement Date
|
18/07/22
|
24/02/23
|
22/02/24
|
-
|
-
|
-
|
Last Close Price
4.35
CNY Average target price
6.875
CNY Spread / Average Target +58.05% Consensus |
1st Jan change
|
Capi.
|
---|
| -33.38% | 39Cr | | +55.32% | 82TCr | | +43.36% | 64TCr | | -6.75% | 35TCr | | +13.56% | 31TCr | | +10.68% | 30TCr | | +16.09% | 24TCr | | +2.09% | 22TCr | | +13.16% | 22TCr | | +8.48% | 17TCr |
Other Pharmaceuticals
|